Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 in genetically defined familial primary hypoalphalipoproteinemia
NL-OMON46978Phase 3Active, not recruiting
- Sponsor
- ABIONYX Pharma
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypoalphalipoproteinaemia (FHA) and Hypo-HDL cholesterolemia (HALP) comparing CER-001 with Placebo (2 arms). Primary endpoints: Change from baseline in carotid mean vessel wall area at 24 weeks and Safety and tolerability at 24 weeks. Started Dec 2015; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
familial hypoalphalipoproteinaemia (FHA)Hypo-HDL cholesterolemia (HALP)
Beyond the preview
Go deeper on NL-OMON46978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46978.